Targeted cancer therapy opens up a new idea for the treatment of tumor.Due to its unique size effects,nanomedicine can take advantage of the enhanced permeability and retention effect(EPR)to preferably accumulate in tumor tissue after systematic administration.To further improve this targeting efficacy,some targeting ligands are often attached on the surface of nanomedicine.It is expected that these ligands can recognize and bind to the target for active targeting therapy.However,in vivo Targeted cancer therapy opens up a new idea for the treatment of tumor. Due to its unique size effects, nanomedicine can take advantage of the enhanced permeability and retention effect (EPR) to preferably accumulate in tumor tissue after systematic administration. efficacy, some targeting ligands are often attached on the surface of nanomedicine. It is expected that these ligands can recognize and bind to the target for active targeting therapy. Host, in vivo